Cyclerion Therapeutics Completes $24 Million Private Placement
– Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease –
– IW-6463 translational pharmacology and olinciguat STRONG Phase 2 top line clinical study results remain on track for late summer and late Q3 2020, respectively
CAMBRIDGE, Mass., July 30, 2020 — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced a direct private sale of $24 million of Cyclerion shares of common stock to Slate Path Capital LP and Pappas Capital.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.